Literature DB >> 17942910

EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.

Xiaoyong Huang1, Yoshihiro Yamada, Hiroyasu Kidoya, Hisamichi Naito, Yumi Nagahama, Lingyu Kong, Shin-Ya Katoh, Weng-lin Li, Masaya Ueno, Nobuyuki Takakura.   

Abstract

EphB4 receptor and its ligand ephrinB2 play an important role in vascular development during embryogenesis. In blood vessels, ephrinB2 is expressed in arterial endothelial cells (EC) and mesenchymal supporting cells, whereas EphB4 is only expressed in venous ECs. Previously, we reported that OP9 stromal cells, which support the development of both arterial and venous ECs, in which EphB4 was overexpressed, could inhibit ephrinB2-positive (ephrinB2+) EC development in an embryonic tissue organ culture system. Although the EphB4 receptor is expressed in a variety of tumor cells, its exact function in regulating tumor progression has not been clearly shown. Here we found that overexpression of EphB4 in B16 melanoma cells suppressed tumor growth in a s.c. transplantation tumor model. Histologic examination of these tumors revealed that EphB4 overexpression in B16 cells selectively suppressed arterial ephrinB2+ EC development. By coculturing ephrinB2-expressing SV40-transformed mouse ECs (SVEC) with EphB4-overexpressing B16 cells, we found that EphB4 induced the apoptosis of SVECs. However, ephrinB2 did not induce the apoptosis of EphB4-overexpressing B16 cells. Based on results from these experiments, we concluded that EphB4 overexpression in B16 tumor cells suppresses the survival of arterial ECs in tumors by a reverse signaling via ephrinB2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942910     DOI: 10.1158/0008-5472.CAN-07-0531

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand.

Authors:  Nai-Ying Yang; Pablo Lopez-Bergami; James S Goydos; Dana Yip; Ameae M Walker; Elena B Pasquale; Iryna M Ethell
Journal:  Pigment Cell Melanoma Res       Date:  2010-07-23       Impact factor: 4.693

2.  EphB4 expression in pterygium is associated with microvessel density.

Authors:  Chunyan Xue; Yueqin Chen; Zhenping Huang; Yirui Ge; Haiyan Wang; Jiandong Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

3.  Soluble ephrin-B2 mediates apoptosis in retinal neovascularization and in endothelial cells.

Authors:  Michael H Davies; David O Zamora; Justine R Smith; Michael R Powers
Journal:  Microvasc Res       Date:  2009-02-13       Impact factor: 3.514

4.  Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.

Authors:  Chaohao Li; Nadia A Lanman; Yifan Kong; Daheng He; Fengyi Mao; Elia Farah; Yanquan Zhang; Jinghui Liu; Chi Wang; Qiou Wei; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2020-03-17       Impact factor: 5.157

Review 5.  Human placental microRNAs and preeclampsia.

Authors:  Dong-bao Chen; Wen Wang
Journal:  Biol Reprod       Date:  2013-05-23       Impact factor: 4.285

6.  The Role of PTEN in Tumor Angiogenesis.

Authors:  Stéphane Rodriguez; Uyen Huynh-Do
Journal:  J Oncol       Date:  2011-09-05       Impact factor: 4.375

7.  Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.

Authors:  Christin Neuber; Birgit Belter; Sebastian Meister; Frank Hofheinz; Ralf Bergmann; Hans-Jürgen Pietzsch; Jens Pietzsch
Journal:  Molecules       Date:  2018-02-17       Impact factor: 4.411

Review 8.  The IGF-II-Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives.

Authors:  Pierluigi Scalia; Antonio Giordano; Stephen J Williams
Journal:  Cancers (Basel)       Date:  2020-02-05       Impact factor: 6.639

9.  Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma.

Authors:  Pierluigi Scalia; Giuseppe Pandini; Vincenzo Carnevale; Antonio Giordano; Stephen J Williams
Journal:  Oncogene       Date:  2019-07-03       Impact factor: 9.867

10.  Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma.

Authors:  Hiroshi Kubo; Shigeki Yagyu; Kayoko Nakamura; Kumiko Yamashima; Akimasa Tomida; Ken Kikuchi; Tomoko Iehara; Yozo Nakazawa; Hajime Hosoi
Journal:  Mol Ther Oncolytics       Date:  2021-03-05       Impact factor: 7.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.